ライフサイエンスコーパス: pulmonary metastasis

1 ificantly reduced HCC progression as well as pulmonary metastasis.

2 a HIF-1-dependent manner in murine models of pulmonary metastasis.

3 Sema7a, there was a significant reduction in pulmonary metastasis.

4 of systemic metastasis and a mouse model of pulmonary metastasis.

5 hibited invasion, anoikis, angiogenesis, and pulmonary metastasis.

6 ctivation in myeloid cell recruitment during pulmonary metastasis.

7 stic of coagulation abnormalities as well as pulmonary metastasis.

8 ant spontaneous mouse model of breast cancer pulmonary metastasis.

9 mor activity in a mouse model of established pulmonary metastasis.

10 e is known about its activity in established pulmonary metastasis.

11 es, is associated with the aggressiveness of pulmonary metastasis.

12 atic human breast cancers, was important for pulmonary metastasis.

13 One patient developed pulmonary metastasis.

14 t phosphorylation, primary tumor growth, and pulmonary metastasis.

15 terization of the genetics and mechanisms of pulmonary metastasis.

16 ooxygenase 2 gene expression associated with pulmonary metastasis.

17 ased tumor latency and increased the rate of pulmonary metastasis.

18 breast cancer cells and depict its effect on pulmonary metastasis.

19 the mammary epithelium resulted in decreased pulmonary metastasis.

20 illaries by circulating tumour cells to seed pulmonary metastasis.

21 on, and enabled highly penetrant spontaneous pulmonary metastasis.

22 ocal mammary tumors with a high incidence of pulmonary metastasis.

23 e response to control Chi3l1 elaboration and pulmonary metastasis.

24 nd a structural basis for cell arrest during pulmonary metastasis.

25 4 blocked DPPIV/poly-FN adhesion and impeded pulmonary metastasis.

26 ressive malignancy with a tendency for early pulmonary metastasis.

27 cal tumor development, stromal invasion, and pulmonary metastasis.

28 f carcinoma and to a significant increase in pulmonary metastasis.

29 s done for hepatic recurrence (28 patients), pulmonary metastasis (20 patients), local recurrence (24

30 TRAP-treated B16F10 tumor cells enhance pulmonary metastasis 41- to 48-fold (n = 17).

31 ely in the lung and observed a wide range of pulmonary metastasis among inbred mouse strains.

32 cancer, HB22.7 inhibited the development of pulmonary metastasis and extended overall survival.

33 This patient underwent resection of a pulmonary metastasis and is alive, 63.6 months from OLT.

34 at there is also a gender difference between pulmonary metastasis and lymph node metastasis showing t

35 In vivo experimental B16-F10 pulmonary metastasis and primary tumor growth assays fou

36 rvations to evaluate the function of CCR5 in pulmonary metastasis and the mechanism underlying the di

37 Ms infiltrating mouse breast tumors prevents pulmonary metastasis and tumor lymphangiogenesis.

38 iod of minimal residual disease, spontaneous pulmonary metastasis, and cell line variants that differ

39 rvival < 30%, except for those with isolated pulmonary metastasis (approximately 50%).

40 d from an experimental murine tumor model of pulmonary metastasis are quantified using a digital imag

41 ancer resected for cure (isolated hepatic or pulmonary metastasis) are candidates for endoscopic surv

42 Here, we describe an ex vivo pulmonary metastasis assay (PuMA) in which the metastati

43 tified melanotic lesions in both primary and pulmonary metastasis B16F10 tumor models.

44 ed with control vaccine had no effect in the pulmonary metastasis burden.

45 demonstrated marked increases (>10-fold) in pulmonary metastasis compared with vector (pLNCX2)-B16 a

46 These data demonstrate an asymptomatic pulmonary metastasis detection rate of 0.099% (95% confi

47 he overall median survival from diagnosis of pulmonary metastasis for all patients was 15 months.

48 cutaneous tumor growth and strongly impaired pulmonary metastasis formation by generating anti-xCT an

49 f EDG2 expression augmented the incidence of pulmonary metastasis from 51.9% to 90.4% (P = 2.4 x 10(-

50 27, and suppressed HCC motility in vitro and pulmonary metastasis in a nude mouse model.

51 ration or viability, and maraviroc decreased pulmonary metastasis in a preclinical mouse model of bre

52 The level of a pulmonary metastasis in BF1 mice increased to the level

53 The level of pulmonary metastasis in BF10 mice or in BF1 mice inocula

54 One possible mechanism of resistance to pulmonary metastasis in BTBRT+tf/J mice may require T-ce

55 These results support a model for pulmonary metastasis in mice in which 1) tumor cells can

56 These results suggest that the severity of pulmonary metastasis in mice receiving B16 melanoma cell

57 cal tumor invasion as well as lymph node and pulmonary metastasis in mouse cancer models.

58 e tumor antigen (Tag) following experimental pulmonary metastasis in naive mice.

59 ion inhibits prostate cancer progression and pulmonary metastasis in TRAMP mice by reducing cell prol

60 icantly inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice without causing any s

61 oma cells we analyzed local tumor growth and pulmonary metastasis in transgenic mice engineered to ov

62 kout mice, whereas KAI1 completely abrogated pulmonary metastasis in wild-type and heterozygous litte

63 ately 50% and 63% decrease, respectively, in pulmonary metastasis incidence and multiplicity compared

64 Pulmonary metastasis is a frequent cause of poor outcome

65 The formation of pulmonary metastasis is greatly facilitated by recruitme

66 The development of pulmonary metastasis is the major cause of death in oste

67 In mouse models of breast cancer pulmonary metastasis, MAMs uniquely express FLT1.

68 of CXCR4 in B16 cells dramatically enhanced pulmonary metastasis, metastasis to the lymph nodes, liv

69 antigen (Tag) within an experimental murine pulmonary metastasis model of SV40 Tag-expressing tumors

70 abrogates MSC homing to tumors in an in vivo pulmonary metastasis model, confirming the in vitro two-

71 We then found, using a pulmonary metastasis model, systemically delivered MSCs

72 wild-type BALB/c mice using an experimental pulmonary metastasis model, we attempted to address whet

73 d in a statistically significant decrease in pulmonary metastasis multiplicity compared with controls

74 poorly differentiated prostate carcinoma and pulmonary metastasis multiplicity in transgenic adenocar

75 e key hemostatic factors on the hematogenous pulmonary metastasis of 2 established murine tumors, Lew

76 ines produced by these cells on experimental pulmonary metastasis of B16 melanoma was investigated in

77 ion of beta3 integrin rescues the growth and pulmonary metastasis of beta1 integrin-deficient 4T1 tum

78 ver an unprecedented role for GALNT14 in the pulmonary metastasis of breast cancer and elucidate the

79 Pulmonary metastasis of breast cancer cells is promoted

80 Pulmonary metastasis of breast cancer requires recruitme

81 the physiologic level of MTA1 in supporting pulmonary metastasis of breast cancer.

82 We confirmed roles for Sema7a and Chi3l1 in pulmonary metastasis of EMT6 breast cancer cells.

83 trated that overexpression of Ang-3 inhibits pulmonary metastasis of Lewis lung carcinoma and TA3 mam

84 ntly decreased the growth, angiogenesis, and pulmonary metastasis of mammary tumors produced in mice.

85 tegrin alpha v beta 5 to promote spontaneous pulmonary metastasis of multiple tumor cell types in bot

86 receptors were both required for spontaneous pulmonary metastasis of multiple tumor types even though

87 le by exogenous RANKL, which also stimulated pulmonary metastasis of RANK(+) human breast cancer cell

88 ted that overexpression of ADAMTS-1 promotes pulmonary metastasis of TA3 mammary carcinoma and Lewis

89 The dependence of pulmonary metastasis on T cells was replaceable by exoge

90 Surface polyFn is critical for pulmonary metastasis, presumably by facilitating lung va

91 osed nascent tumor growth in mouse models of pulmonary metastasis, reflecting systemic lineage-specif

92 Pulmonary metastasis remains the leading ca use of death

93 A 50-year-old man developed progressive pulmonary metastasis resistant to interferon alfa-2b tre

94 und that tumor cell lines derived from focal pulmonary metastasis secreted relatively greater quantit

95 umor immunity in an established experimental pulmonary metastasis setting.

96 Moreover, in a murine model of HCC pulmonary metastasis, stable knockdown of HMGB1 suppress

97 Patterns of distant pulmonary metastasis tended to follow the same patterns

98 rocess, we aimed to develop a mouse model of pulmonary metastasis that can be assayed in multiple inb

99 tumor-derived MIF promotes tumor growth and pulmonary metastasis through control of inflammatory cel

100 expression on CD8(+) T cells and limited B16 pulmonary metastasis to the same degree as PD-1 gene def

101 Confirmation of pulmonary metastasis usually requires serial imaging bec

102 n of MEK-dependent pathways by E(2) leads to pulmonary metastasis via enhanced survival of detached t

103 lete tumor immunity within a murine model of pulmonary metastasis was achieved upon two i.m. injectio

104 Pulmonary metastasis was associated with advanced pathol

105 In mice in protocol B, the incidence of pulmonary metastasis was decreased 1.9-fold (P = 0.069)

106 Pulmonary metastasis was either eliminated or significan

107 fect of treatment on mouse renal cancer cell pulmonary metastasis was investigated.

108 er, a dramatic reduction of tumor growth and pulmonary metastasis was observed after s.c. implantatio

109 The largest reduction in pulmonary metastasis was observed in sphingosine-1-phosp

110 melanoma cell line B16 as a murine model of pulmonary metastasis, we examined whether the pro- versu

111 To define genetic determinants of pulmonary metastasis, we have applied cDNA microarrays t

112 Here, using mouse models of pulmonary metastasis, we identify bone marrow (BM)-deriv

113 57%, 36%, 27%, and 27%; rates for colorectal pulmonary metastasis were 87%, 78%, 57%, 57%, and 57%.

114 AdsGRP94 injections, local tumor growth and pulmonary metastasis were markedly inhibited.

115 ieved increased protection from experimental pulmonary metastasis when NK cells were further activate

116 the expression of receptor IL-13Ralpha2 and pulmonary metastasis while restoring NK cell accumulatio

117 n the mammary epithelium displayed increased pulmonary metastasis, with no differences in tumor onset

118 their sensitivity to apoptosis; and reduces pulmonary metastasis, with no effect on primary tumor gr